Schrödinger, Inc. reports developments tied to its computational platform for molecular discovery, which is licensed to biotechnology, pharmaceutical, industrial and academic customers for drug development and materials design. Company updates commonly cover Software segment performance, hosted and license-server delivery, annual contract value, and the role of software revenue in the business.
News also addresses Schrödinger's Drug Discovery segment, including collaborative and internal programs, together with clinical or regulatory disclosures when applicable. Recurring corporate items include quarterly and annual financial results, investor conference participation, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), shareholder voting matters, governance changes and capital-structure disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Schrödinger (Nasdaq: SDGR) is set to release its first quarter 2023 financial results on May 4, 2023, after market close. A conference call will follow at 4:30 p.m. ET. Investors can access the live webcast on the company's website and by phone using conference ID 21402709. Schrödinger employs a physics-based computational platform to expedite the discovery of new therapeutics and materials, significantly reducing time and costs compared to traditional methods. Founded in 1990, the company has around 800 employees and collaborates with clients across more than 70 countries. To explore further, visit www.schrodinger.com.